<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20130">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844842</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-ALE-2016-01</org_study_id>
    <nct_id>NCT02844842</nct_id>
  </id_info>
  <brief_title>Evaluation of Tolerability and Safety of &quot;Allergovac Poliplus&quot; in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice</brief_title>
  <acronym>APOLO</acronym>
  <official_title>Evaluation of Tolerability and Safety of &quot;Allergovac Poliplus&quot; in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BIAL Industrial Farmacéutica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BIAL Industrial Farmacéutica S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational prospective study to assess the tolerability and safety of
      treatment of SCIT Allergovac Poliplus polymerized in depot presentation. The study drug will
      be administered either by a 1 day Schedule or by a rapid Schedule (3 increasing weekly doses
      at initiation period till maintenance dose is reached) The study population is both: adult
      and child, polysensitized to at least 2 allergen sources with rhinitis or allergic
      rhinoconjunctivitis. Patients may also present a concomitant mild or moderate asthma.

      The assignment of a patient to a particular therapeutic strategy will not be decided in
      advanced by a trial protocol but will be determined by routine clinical practice. The
      decision of the investigator to prescribe a particular treatment will be clearly dissociated
      from the decision to include the patient in the study. The patients will not suffer any
      intervention, whether diagnostic or monitoring, other than the usual in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 23, 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse drug reactions</measure>
    <time_frame>From patient ICF signature till 1 week after last administered dose</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1 day initiation schedule</arm_group_label>
    <description>The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid initiation schedule</arm_group_label>
    <description>The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac Poliplus</intervention_name>
    <arm_group_label>1 day initiation schedule</arm_group_label>
    <arm_group_label>Rapid initiation schedule</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Polisensitized patients with allergic rinitis and rhinoconjunctivitis with or without
        associated mild or moderate asthma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged between 5 and 60 years who present rhinitis or allergic
             rhinoconjunctivitis caused by IgE-mediated sensitization to more than one allergen
             source with or without mild / moderate asthma.

          2. Patients eligible for immunotherapy treatment with Allergovac Poliplus according to
             investigator criteria.

          3. Patients must provide written informed consent. It is the case of children , the
             legal representative or tutor of the child must sign the inform consent form.

        Exclusion Criteria:

          1. Patients that according to the investigator criteria may present difficulties for
             understanding the patient information sheet, completing the questionnaires and
             self-administered scales.

          2. Patients that according to the investigator may present difficulties to complete the
             patient diary.

          3. Patients who are participating in another clinical trial or observational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leire Begoña, MSc</last_name>
    <phone>00346005005873</phone>
    <email>leire.begona@bial.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Begoña Madariaga, MD</last_name>
    <phone>0034944438000</phone>
    <email>begona.madariaga@bial.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>C.H.U A Coruña</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Parra</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Garriga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopsital de Vinalopó</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mónica Antón</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Dr. Arias Irigoyen</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Dra. Victoria Moreno</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Lugo</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramón Nuñez Orjales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica de Asma y Alergia Dres. Ojeda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Ojeda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Elena</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aythamy Henriquez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriela Canto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Rodriguez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matilde Rodriguez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatriz Rodriguez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Onteniente</name>
      <address>
        <city>Onteniente</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan José Liñana</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Tórax</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ntra. Sra de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaspar Dalmau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Ibero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Alvariño</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Xátiva</name>
      <address>
        <city>Xátiva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Ángel Navarro</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>July 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild or moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
